Register / Log In

Xeomin cleared to re-enter U.S. market


Greensboro, N.C. — Having reached the end of a 10-month injunction barring it from selling its botulinum toxin product in the U.S., Merz is once again launching Xeomin for the treatment of glabellar lines.

Xeomin (incobotulinumtoxinA) was shelved in the U.S. in March 2012 after a federal court concluded Merz stole trade secrets such as customer lists and sales figures from Allergan, maker of Botox (onabotulinumtoxinA), in 2010. Merz was accused of collecting the information from former Allergan sales representatives, Bloomberg reports.

The Food and Drug Administration approved Xeomin in July 2011 for the temporary improvement of moderate-to-severe glabellar lines. With the court order lifted, Merz may now promote the sale of Xeomin with no restrictions. The product will join the likes of Dysport (abobotulinumtoxinA, Medicis), another rival for Botox that is available in the United States.

Intermittent dosing of vemurafenib extended the lives of lab mice with drug-resistant melanoma tumors, according to results of an international study.

Atopic dermatitis coupled with food allergy in early childhood speeds up allergic progression, according to findings from a recent study.

Patients with rheumatoid arthritis who use anti-tumor necrosis factor treatments may have an increased risk of shingles, according to researchers.